PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

NOVAVAX Announces Release Date of 2010 Year-End Financial Results and Investor Conference Call

ROCKVILLE, Md., March 23, 2011 /PRNewswire via COMTEX/ --

Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2010 year-end financial results in a press release to be issued after 8:00 a.m. local time Monday, March 28, 2011 and will then hold an investor conference call at 10:00 a.m. The call will be hosted by Novavax's President and Chief Executive Officer, Dr. Rahul Singhvi and other members of senior management. The dial-in number for the conference call is 1 (877)-212-6076 (U.S. or Canada) or 1 (707)-287-9331 (International).

A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. A replay of the conference call will be available on Novavax's website approximately one-hour after the event for 90 days and a replay will also be available by telephone beginning March 28, 2011. To access the replay, dial 1-(800)-642-1687 and enter pass code 54520344.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.

Accept